SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-18-143140
Filing Date
2018-04-30
Accepted
2018-04-30 16:13:04
Documents
11
Effectiveness Date
2018-04-30

Document Format Files

Seq Description Document Type Size
1 DEFA14A d578654ddefa14a.htm DEFA14A 29801
2 GRAPHIC g578654a1.jpg GRAPHIC 4011
3 GRAPHIC g578654a2.jpg GRAPHIC 3857
4 GRAPHIC g578654a3.jpg GRAPHIC 4185
5 GRAPHIC g578654a4.jpg GRAPHIC 3032
6 GRAPHIC g578654b1.jpg GRAPHIC 4204
7 GRAPHIC g578654b2.jpg GRAPHIC 809
8 GRAPHIC g578654b3.jpg GRAPHIC 4301
9 GRAPHIC g578654b4.jpg GRAPHIC 857
10 GRAPHIC g578654b5.jpg GRAPHIC 686
11 GRAPHIC g578654b6.jpg GRAPHIC 3917
  Complete submission text file 0001193125-18-143140.txt   73345
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35703 | Film No.: 18789837
SIC: 2834 Pharmaceutical Preparations